Pulse Biosciences (NASDAQ:PLSE) Shares Up 7.3%

Pulse Biosciences, Inc. (NASDAQ:PLSE)’s share price rose 7.3% during trading on Thursday . The stock traded as high as $10.74 and last traded at $10.70. Approximately 32,514 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 199,633 shares. The stock had previously closed at $9.97.

Analysts Set New Price Targets

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a research report on Thursday.

Pulse Biosciences Price Performance

The stock has a 50-day moving average of $10.06 and a 200-day moving average of $9.55.

Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Tuesday, May 7th. The company reported ($0.17) earnings per share (EPS) for the quarter.

Insiders Place Their Bets

In related news, CEO Burke Thomas Barrett acquired 10,000 shares of the stock in a transaction on Monday, May 20th. The stock was acquired at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,000 shares of the company’s stock, valued at approximately $85,600. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 71.50% of the stock is currently owned by company insiders.

Institutional Trading of Pulse Biosciences

A number of hedge funds have recently made changes to their positions in PLSE. BNP Paribas Financial Markets boosted its position in shares of Pulse Biosciences by 63.6% in the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock worth $66,000 after purchasing an additional 2,952 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new stake in shares of Pulse Biosciences in the 1st quarter worth approximately $88,000. Cetera Advisors LLC bought a new position in Pulse Biosciences in the 1st quarter valued at approximately $109,000. PNC Financial Services Group Inc. bought a new position in Pulse Biosciences in the 4th quarter valued at approximately $242,000. Finally, Inspire Investing LLC lifted its position in Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after acquiring an additional 10,039 shares in the last quarter. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.